I am currently a Diagnostic Hematopathologist at Brigham and Women's Hospital and Dana Farber Cancer Institute (DFCI) and an Associate Professor of Pathology at Harvard Medical School. I am the Associate Medical Director of the Clinical Hematology Laboratory at BWH and the Medical Director of the Physicians Diagnostic Laboratories at Brigham and Women’s Harbor Medical Associates (HMA) and DFCI Cancer Center and the Community Cancer Care in Weymouth.
As a member of the Hematopathology Division at BWH and a Hematopathologist, I provide comprehensive diagnostic evaluation of patients specimens, including conventional histology, as well as specialized immunological, molecular and flow cytometric tests, that result in an integrated diagnostic reports. My particular clinical expertise lies in myeloproliferative neoplasms and I am frequently consulted by my colleagues and pathologists at outside institutions. In addition, I participate in direct day-to-day instruction and education in all aspects of Hematopathology and Clinical Hematology to the fellows and residents. I also present weekly interactive clinical case conferences within the Division of Hematopathology and DFCI clinical pathologic correlation conferences. I am the course director of a bi-weekly Hematology Laboratory and Coagulation Journal Club with pathology trainees, faculty and laboratory staff. I also serve as a tutor in the Human Systems Course at Harvard Medical School. I have organized and lectured in courses at several national and international pathology conferences, including the College of American Pathologists and American Society of Clinical Pathologists. I have co-authored a textbook Hematopathology: A Volume in the High Yield Pathology Series and have authored chapters in numerous Hematology and Pathology textbooks.
My research efforts are focused on the development and application of novel approaches to diagnosing and prognostication of hematologic diseases, with specific interest in myeloid neoplasms. Using a novel gene expression platform, I analyze the contribution of the inflammatory microenvironment to the pathogenesis of myeloproliferative neoplasms. I serve as a central pathologist reviewer in several clinical trials of novel therapeutic agents for myeloproliferative neoplasm. I am also studying novel hematologic parameters on Sysmex hematology analyzers that could be used as diagnostic screening tests for cytopenic patients, potentially avoiding unnecessary and costly tests in the workup of this common clinical scenario.